drugset / Trial / NCT03704688
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
Timeline
- Start
- 2018-10-09
- Primary completion
- 2022-02-04
- Completion
- 2022-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponatinib | Small molecule | 15 mg | Oral |
| Subject | Ponatinib | Small molecule | 30 mg | Oral |
| Subject | Trametinib | Small molecule | 0.5 mg | Oral |
| Subject | Trametinib | Small molecule | 1 mg | Oral |
| Subject | Trametinib | Small molecule | 1.5 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |